Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Heart Matters

Semaglutide reduces MACE in patients with obesity or overweight and prior CABG

Subodh Verma
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    AHA 2024 - Subodh Verma shares the results of a sub-analysis from the SELECT trial in patients who had a prior history of CABG.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, ON, Canada. 

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Release date: 19 November 2024

Recommended
Details
Presenters
Comments
  • Overview

    AHA 2024 - Subodh Verma shares the results of a sub-analysis from the SELECT trial in patients who had a prior history of CABG.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, ON, Canada. 

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Release date: 19 November 2024

Schedule1 Dec 2024